Tesamorelin vs Sermorelin
Two GHRH analogs with approval histories. Which one still earns the price?
Reviewed by the amino101 editorial team. , first published .
Tesamorelin and sermorelin are the two GHRH analogs with a regulatory history, and they are the ones clinics prescribe. Both act on the same GHRH receptor in the pituitary and both leave the body's feedback loop intact, so IGF-1 rises but rarely overshoots. The differences are stability and evidence. Sermorelin is the bare GRF 1-29 fragment, cleared by DPP-IV within 10 to 20 minutes; it was FDA approved as Geref for diagnosing and treating growth hormone deficiency until the manufacturer withdrew it in 2008 for commercial reasons. Tesamorelin is the full 44 amino acid sequence with an N-terminal modification that roughly doubles its stability, and it is currently approved as Egrifta for HIV associated lipodystrophy on the strength of two phase 3 trials showing visceral fat reduction of about 15 to 18 percent. Sermorelin is cheaper and gentler. Tesamorelin is stronger, more expensive, and the one with fat loss evidence. Both are prohibited by WADA. This is an educational comparison, not a prescription.
| Tesamorelin | Sermorelin | |
|---|---|---|
| Typical dosage | 1 to 2 mg | 200 to 500 mcg |
| Frequency | once daily | once daily |
| Route | Subcutaneous | Subcutaneous |
| Half-life | 26 to 38 minutes in plasma | 10 to 20 minutes in plasma |
| Cycle | ongoing; reassess at 3 to 6 months with IGF-1 and waist measurements | 3 to 6 months |
| Research level | Extensively studied | Extensively studied |
| Human trials | Approved drug | Approved drug |
| Status | FDA approved (Egrifta) for HIV-associated lipodystrophy; off-label otherwise | Formerly FDA approved (Geref, withdrawn 2008); widely available via compounding pharmacies |
| Effects timeline | IGF-1 rise 2 to 4 weeks, waist and visceral fat change 12 to 26 weeks | sleep quality 1 to 2 weeks, IGF-1 rise on bloodwork 4 to 6 weeks, body composition and skin 2 to 3 months if at all |
Key differences
Tesamorelin vs Sermorelin dosage
Dosage patterns reported in research and community protocols, by goal. Taken from each compound page. Not a prescription.
| Goal | Dosage | Frequency |
|---|---|---|
| Approved dose | 2 mg | once daily |
| Reduced dose for cost or side effects | 1 mg | once daily |
| Stacked with a GHRP | 1 to 2 mg | once daily before bed, with 100 mcg ipamorelin |
| Maintenance after fat loss | 1 mg | once daily, or 2 mg on alternating days |
| Goal | Dosage | Frequency |
|---|---|---|
| Clinic standard | 200 to 300 mcg | once daily before bed |
| Higher single dose | 500 mcg | once daily before bed |
| Stacked with a GHRP | 200 mcg | once daily before bed, with 100 mcg ipamorelin |
| 5 on 2 off variant | 300 mcg | once daily, weekdays only |
Convert any of these to syringe units in the dosage calculator.
Side effects compared
- ▲Injection site redness, itching, bruising, or irritation
- ▲Joint pain and stiffness
- ▲Swelling in the hands and feet, carpal tunnel symptoms
- ▲Elevated blood glucose in susceptible people
- ▲Headache or flushing
- ▲Injection site redness, itching, or small lumps
- ▲Flushing or warmth shortly after a dose
- ▲Headache or dizziness
- ▲Mild water retention
- ▲Drowsiness, which is why bedtime dosing is preferred
Which should you choose?
Tesamorelin fits someone targeting abdominal fat who wants trial evidence and accepts the cost of 1 to 2 mg daily. It is the stronger GHRH analog, with a half-life roughly double sermorelin's and a pulse that does not depend as heavily on perfect timing. Monitor fasting glucose and expect injection site irritation.
Sermorelin fits people who want the gentlest, cheapest GHRH analog, who are working through a clinic, or who are new to secretagogues and want to see how they respond before spending more. 200 to 300 mcg at bedtime on an empty stomach is the common clinic dose. Expect a modest effect and plan to add ipamorelin if the pulse feels too small.
Tesamorelin is the better drug and sermorelin is the better deal, and which matters depends on the goal. For visceral fat, there is no contest: tesamorelin has the phase 3 trials, sermorelin has nothing comparable, and the price is the price. For general GH support, sleep, or a clinic managed anti-aging protocol where the aim is a modest IGF-1 rise over months, sermorelin does the job at a fraction of the cost and with a gentler side effect profile. Its weakness is potency: each dose produces a smaller, less reliable pulse because the unmodified peptide is degraded within minutes. Most self directed users who compare them end up on tesamorelin or Mod GRF 1-29 for that reason. Whichever GHRH analog you choose, adding ipamorelin turns a modest pulse into a large one, and that pairing is the real protocol. The peptide dosage chart lists the reported ranges for all the secretagogues side by side.
Stacking: Not stacked with each other; they hit the same receptor and adding one to the other does little. Either is paired with ipamorelin before bed.
Tesamorelin is a stabilized growth hormone releasing hormone analog approved as Egrifta to reduce belly fat in people with HIV-related lipodystrophy. It is the GHRH analog with the strongest human evidence, and people use it off-label for visceral fat loss and general growth hormone support.
Sermorelin is the first 29 amino acids of natural growth hormone releasing hormone, the shortest fragment that still fully activates the receptor. It was once an approved diagnostic and pediatric drug and is now the most common growth hormone secretagogue prescribed by anti-aging and wellness clinics.
Tesamorelin vs Sermorelin: frequently asked
Is tesamorelin stronger than sermorelin?
Yes. The N-terminal modification protects tesamorelin from DPP-IV, so each dose produces a larger and more reliable GH pulse than unmodified sermorelin, which is cleared in 10 to 20 minutes. Tesamorelin is also dosed several times higher by weight.
Can you take tesamorelin and sermorelin together?
There is no reason to. Both act on the GHRH receptor, so stacking them adds little beyond cost. The useful pairing for either is a GHRP like ipamorelin, which acts on a different receptor and multiplies the pulse.
Which is better for fat loss, tesamorelin or sermorelin?
Tesamorelin, by a wide margin on evidence. It has phase 3 trials showing visceral fat reduction; sermorelin has older trials showing modest lean mass gains in adults over 55 but no fat loss trial. Neither approaches GLP-1 drugs for total weight loss.
Why do clinics prescribe sermorelin instead of tesamorelin?
Cost, availability and regulatory comfort. Sermorelin has an approval history, is easy to compound, and is cheap at 200 to 300 mcg nightly. Tesamorelin is a current branded drug with an HIV specific label, so off label prescribing is more expensive and less routine.
Do tesamorelin and sermorelin raise blood sugar?
Tesamorelin can in susceptible people, and the label advises monitoring; sermorelin's older trials did not flag it as a common problem, likely because the GH rise is smaller. Both are contraindicated in active cancer and in anyone with a disrupted pituitary axis.
Related reading
Visceral fat loss with growth hormone support
One is a GHRP, one is a GHRH analog. Why are they compared, and why are they usually combined?
An approved GHRH analog with fat loss trials versus the community's favorite GHRP.
Inject the hormone itself, or ask your pituitary to make more? The trade-offs are not subtle.
Both are sold for belly fat. One failed its phase 2 trials and one is an approved drug. Which is which, and does the failed one add anything?
GLP-1
Sources
- Tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled analysis of two Phase 3 trials. Journal of Acquired Immune Deficiency Syndromes, 2010
- Effects of nightly GHRH 1-29 administration in healthy older men and women. Journal of Clinical Endocrinology and Metabolism, 1997
- Egrifta (tesamorelin for injection) prescribing information. US Food and Drug Administration, 2010